(p. A3) The cancer mortality rate in the U.S. has dropped by a third in the past three decades, a report showed, but an increase in advanced prostate cancer diagnoses threatens to reverse some hard-won gains.
The American Cancer Society said Thursday [Jan. 12, 2023] that changes in preventive measures and screening in the past decade drove important trends in U.S. cancer incidence and outcomes.
. . .
The report was published in the journal CA: A Cancer Journal for Clinicians. The authors at ACS analyzed federal and state cancer registries for data on cancer rates through 2019 and federal mortality data through 2020, the report said.
Cancer is the second-leading cause of death in the U.S., behind heart disease, with nearly 2 million cases and some 610,000 deaths estimated to occur in 2023, the ACS said. The decline in smoking rates in the U.S., better early detection and innovative treatments including immunotherapy drugs have driven a drop in death rates since 1991, the report said, averting an estimated 3.8 million cancer deaths in that time.
. . .
For prostate cancer, the second leading cause of cancer death among men after lung cancer, rates of advanced diagnoses have risen about 4.5% annually since 2011, the report found. The proportion of men diagnosed with later-stage disease has doubled. Declines in mortality rates have leveled off.
For the full story, see:
(Note: ellipses, and bracketed date, added.)
(Note: the online version of the story has the date January 12, 2023, and has the title “U.S. Cancer Death Rate Has Dropped by a Third Since 1991.”)